Delving into the Latest Updates on Ivermectin with Synapse

Overview

Basic Info

SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity.

Drug Type

Small molecule drug

Synonyms

mdc-STM, CD-5024, K-237

+ [13]

Target

GluCls

Action

modulators

Mechanism

Glutamate-gated chloride channel modulators

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesSkin and Musculoskeletal Diseases+ [3]

Active Indication

RosaceaLice InfestationsScabies+ [10]

Inactive Indication

Acne VulgarisDermatitis, AtopicPediculus capitis infestation

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Zhejiang Hisun Pharmaceutical Co., Ltd.

Merck Sharp & Dohme Corp.Merck Sharp & Dohme (Australia) Pty Ltd.

+ [9]

Inactive Organization

Galderma Research & Development SNC

Galderma Holding SATaro Pharmaceuticals U.S.A., Inc.

+ [2]

License Organization

Medicines Patent Pool Foundation

MedinCell SA

Sol-Gel Technologies Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (22 Nov 1996),

OnchocerciasisStrongyloidiasis

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS Registry70209-81-3

This is a clinical trial to compare two formulations of the drug ivermectin: the standard 3mg tablet formulation versus a newly developed infant formula preparation. The goal of the trial is to determine if the new formulation functions in the same way, tastes the same and causes no new side effects. The trial will involve 52 participants who will be healthy adult volunteers. The participants will receive both formulations - the order they receive each formulation will be assigned randomly (similar to the toss of a coin).

Start Date01 May 2026

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+1]

NCT07396714

/ Not yet recruitingEarly Phase 1IIT

Evaluation of the Efficacy & Safety of Topical Ivermectin Alone or in Combination With Microneedling as Novel Therapeutic Options for Cutaneous Non-genital Warts Versus Topical Salicylic Acid ؛ Randomized Controlled Clinical Trial.

To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts.
topical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks
Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue.
Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)

Start Date01 Feb 2026

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Ivermectin

Login to view more data

100 Translational Medicine associated with Ivermectin

Login to view more data

100 Patents (Medical) associated with Ivermectin

Login to view more data

7,220

Literatures (Medical) associated with Ivermectin

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Chen, Xiang ; Li, Sitong ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

01 Feb 2026·CHEMOSPHERE

Unveiling new abilities of actinobacteria: Proficiency in the bioremoval of the emerging contaminant ivermectin

Article

Author: González Holc, Victoria Guadalupe ; Arnau, Gonzalo ; Polti, Marta Alejandra ; Small, María Alejandra ; Benimeli, Claudia Susana ; Aparicio, Juan Daniel

Emerging contaminants are synthetic or natural compounds that remain largely unregulated in the environment but may pose ecological and health risks. Among them is ivermectin, widely used to treat bovine parasitosis and, more recently, human viral infections. Bioremediation using actinobacteria represents a promising strategy for removing such compounds, given their remarkable metabolic versatility and ability to detoxify contaminants. This study aimed to evaluate the ability of actinobacteria to remove ivermectin. A qualitative screening assay was conducted using 12 strains on solid media. Nine of them showed tolerance and were subsequently cultured in liquid medium supplemented with ivermectin (0.1 g L^-1), either as the sole carbon source or in combination with glucose, at 30 °C for 7 days under agitation. In parallel, a robust and validated HPLC-based method for ivermectin extraction and quantification was established. The strains showed differential performance when cultured with either ivermectin or ivermectin plus glucose. Notably, five strains showed growth using ivermectin as the sole carbon source. Among them, Streptomyces spp. ER1 and SG1 achieved the highest rates of ivermectin removal in the presence of glucose, reaching 84 % and 61 % elimination, respectively. This study provides the first evidence of Streptomyces strains capable of utilizing IVM as a sole carbon source and achieving high removal rates via co-metabolism, highlighting their unique potential for bioremediation applications.

01 Feb 2026·VETERINARY PARASITOLOGY

Integrated pharmacokinetic–pharmacodynamic analysis of macrocyclic lactones in sheep infested with resistant Psoroptes ovis

Article

Author: Miró, Victoria ; Herrera, Rodolfo ; Lifschitz, Adrián ; Larroza, Marcela

The current study aimed to investigate the pharmacokinetic/pharmacodynamic (PK/PD) relationship of five macrocyclic lactone (MLs) formulations, three 1 % formulations (ivermectin, doramectin and moxidectin) and two long-acting 3.15 % products (ivermectin and doramectin), against sheep experimentally infested with resistant Psoroptes ovis under standardized doses. Thirty naïve Merino sheep were experimentally infested and randomly assigned to five treatment groups (n = 6). Baseline mite counts were not used to block animals during group allocation. The three 1 % formulations of ivermectin (IVM), doramectin (DRM), and moxidectin (MXD), were administered off-label at a dose of 0.5-0.6 mg/kg on days 0 and 7, subcutaneously. The long-acting 3.15 % formulations were subcutaneously administered once at their approved doses of 1.05 mg/kg (IVM 3.15 %) and 1.26 mg/kg (DRM 3.15 %). Plasma drug concentrations and mite counts were assessed between 0 and 35 days post-treatment. Conventional 1 % formulations produced higher peak plasma concentrations than long-acting formulations, although the latter showed greater persistence, similar to that observed with repeated MXD 1 %. DRM 1 % showed greater systemic exposure compared to 3.15 % long acting formulations and IVM 1 %. Significant reductions in mite counts were observed by day 7 with DRM 1 %, and by day 14 with IVM 1 % and MXD 1 %. In contrast, long-acting formulations showed delayed responses, with significant reductions only by day 21. Only DRM 1 % and MXD 1 % achieved 100 % efficacy. PK/PD indices established for ML-resistant P. ovis were calculated as the ratio between peak plasma concentration (Cmax) and the minimal inhibitory concentration (MIC) values of 15 and 30 ng/mL (Cmax/MIC), as well as the ratios between the area under the concentration-time curve (AUC) and the same MIC values (AUC/MIC). The Cmax/MIC ratio observed for 1 % formulations were significantly higher compared to those obtained with the long-acting formulations at both MIC levels. For the AUC/MIC parameter, the 1 % formulations exhibited significantly higher values compared to the long-acting formulations for the MIC 30 ng/mL.These findings suggest that both the magnitude and duration of MLs in plasma are critical for efficacy against P. ovis.

110

News (Medical) associated with Ivermectin

23 Feb 2026

·www.biospace.com

Kennedy Ally Departs CDC Amid Leadership Shake-Up

iStock, Anton Vierietin Ralph Abraham, a vocal vaccine skeptic who served at the agency for just three months, has stepped down due to “unforeseen family obligations,” according to the CDC. Another domino has fallen at the CDC, with Principal Deputy Director Ralph Abraham stepping down effective immediately, the public health organization announced Monday morning. Last week, acting CDC Director Jim O’Neill left his position. That left Abraham as the most senior leader at the agency until National Institutes of Health Director Jay Bhattacharya assumed leadership of the CDC on an acting basis on Friday. Abraham, a physician, former Congressman and recent surgeon general of Louisiana, was sworn in by Health and Human Services Secretary Robert F. Kennedy Jr. on December 15, 2025 . Now, just a few months later, he has stepped down due to “unforeseen family obligations,” according to the CDC’s brief statement announcing the departure. “Dr. Abraham led with clarity and discipline, advancing the CDC’s mission to protect the health and safety of the American people,” the statement said. “He worked directly with career staff and public health partners to strengthen national preparedness and improve the country’s emergency response efforts.” Abraham is a longtime ally of President Donald Trump and of Kennedy, according to reporting from NPR . Abraham is also a noted skeptic of vaccines and campaigned against COVID-19 shots during the pandemic. In his role as surgeon general of Louisiana, he banned all vaccine promotion campaigns, including COVID, flu and mpox. Abraham also encouraged the use of ivermectin as a treatment for COVID, an idea that was thoroughly debunked using clinical evidence.

Executive ChangeVaccine

21 Jan 2026

·www.prnewswire.com

Primera Professional Pharmacy Introduces the Demovectin™ Kit

ROSENBERG, Texas, Jan. 21, 2026 /PRNewswire/ -- Primera® Professional Pharmacy, a full-service pharmacy specializing in pharmaceutical compounding, announces the availability of the Demovectin™ Kit, a topical prescription ointment kit designed for lids and lashes and dispensed exclusively through Primera Professional Pharmacy. The Demovectin™ Kit features a custom compounded topical medicated ointment containing Ivermectin 1%, Metronidazole 0.5%, and Tea Tree Oil 0.3%, packaged alongside two trusted OCuSOFT® products to support a comprehensive eyelid hygiene routine. The kit includes: Demovectin™ Topical Medicated Ointment A prescription topical ointment formulated with Ivermectin 1%, Metronidazole 0.5%, and Tea Tree Oil 0.3% for lids and lashes. OCuSOFT® Lid Scrub® Oust® Pre-Moistened Pads A non-irritating eyelid cleanser with tea tree oil to remove oil, debris, pollen, and desquamated skin from the eyelids. OCuSOFT® Dry Eye Mask Premium A moist heat mask compress featuring a patent-pending cross-hatch design engineered to deliver even heat distribution. The Demovectin™ Kit is dispensed as a prescription and is available with no minimum orders, no prior authorizations, and free shipping through Primera Professional Pharmacy. Custom compounded prescriptions offered by Primera Professional Pharmacy are prepared in accordance with Section 503A of the Federal Food, Drug, and Cosmetic Act. These compounded medications are not FDA-approved and have not undergone FDA premarket review for safety, effectiveness, or quality. Compounded medications are intended for professional use only and are not essential copies of commercially available products. Healthcare professionals may prescribe the Demovectin™ Kit via phone, fax, or e-scribe through Primera Professional Pharmacy. To learn more about Primera Professional Pharmacy, visit . About Primera® Professional Pharmacy Primera® Professional Pharmacy is a full-service pharmacy specializing in pharmaceutical compounding offering an integrated service model that delivers therapeutic solutions to both doctors and patients, fostering a collaborative relationship pharmacist. Advanced pharmacy software allows prescription status reports and increased patient compliance, helping to improve therapeutic outcomes Contact: Paula Hooper, PharmD, Pharmacist in Charge Phone: 800-233-5469 Email: [email protected] SOURCE Primera Professional Pharmacy 21% more press release views with Request a Demo

02 Dec 2025

·www.biopharmadive.com

Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair

Today, a brief rundown of news from Janux Therapeutics and the Department of Health and Human Services, as well as updates from Eli Lilly and AstraZeneca that you may have missed.Shares of Janux Therapeutics fell nearly 50% on Tuesday after the company reported new early-stage results for a type of masked T cell engager its developing for advanced prostate cancer. Januxs drug, JANX007, was associated with a response rate of 30% among 27 evaluable patients in its latest data cut, down from the 50% response rate disclosed last December. Janux also didnt reveal which responses were unconfirmed, or not corroborated by a subsequent scan. While acknowledging those criticisms as fair, William Blair analyst Matt Phipps countered that, in patients who were treated with the dosing regimens advancing into further testing, or who had a lower tumor burden, the data still suggest JANX007 has a possible best-in-disease profile. The selloff is an overreaction, he wrote in a client note. Ben FidlerThe U.S. Department of Health and Human Services named Martin Kulldorff the chief science officer for the in-house group, known for short as ASPE, that guides the agency on health policy. Kulldorff has been chairing the influential panel, ACIP, that Robert F. Kennedy Jr. recast with vaccine skeptics. His job leading ACIP has been handed to Kirk Milhoan, a pediatric cardiologist who has been critical of COVID-19 vaccines and promoted the use of unproven drugs like hydroxychloroquine and ivermectin to treat the disease during the pandemic. ACIP will meet later this week to discuss the childhood immunization schedule and hepatitis B shots. Ben FidlerEli Lilly said Monday it is dropping the price of the single-dose vials of obesity drug Zepbound that it sells to cash-paying customers through its online channel. According to Lilly, those customers will now pay $299 a month for a starter dose and a maximum of $499 monthly afterwards. The announcement comes less than a month after the Indianapolis-based drugmaker reached an agreement with the Trump administration to lower Zepbound to an average of $346 a month when purchased through a U.S. government cash-pay portal. The new $299 price will apply to the 2.5 milligram weekly starter dose and is down from $349. The 5 milligram dose will now cost $399 instead of $499, while all other doses will be priced at $449. Jonathan GardnerThe Food and Drug Administration will begin reviewing baxdrostat, a blood pressure medication AstraZeneca acquired in a 2023 buyout of CinCor Pharma. The agency has also granted baxdrostat a priority review for its proposed use of treating hard-to-control hypertension, meaning a decision will likely come during the second quarter of 2026, the company said Tuesday. AstraZeneca previously said it expects baxdrostat to eventually generate billions of dollars in yearly sales. It's also being tested as a treatment for primary aldosteronism and in combination with Farxiga for chronic kidney disease and heart failure prevention. Ben Fidler '

VaccineAcquisitionClinical ResultPriority Review

100 Deals associated with Ivermectin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00804	Ivermectin	D11AX22 P02CF01	DB00602

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rosacea	United States	Galderma Laboratories LP	19 Dec 2014
Lice Infestations	United States	Arbor Pharmaceuticals LLC	07 Feb 2012
Scabies	Japan	MSD KK (Tokyo)	21 Aug 2006
Ascariasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Elephantiasis, Filarial	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Enterobiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Helminthiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Hookworm Infections	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Trichuriasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Onchocerciasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996
Strongyloidiasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	Bulgaria	MedinCell SA	25 Mar 2022
Dermatitis, Atopic	Phase 2	Canada	Galderma Holding SA	01 Nov 2016
Dermatitis, Atopic	Phase 2	Canada	Galderma Research & Development SNC	01 Nov 2016
Acne Vulgaris	Phase 2	Canada	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	Canada	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	France	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	France	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	Germany	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	Germany	Galderma Holding SA	25 Apr 2016
Pediculus capitis infestation	Phase 1	United States	Taro Pharmaceuticals U.S.A., Inc.	20 Mar 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04410406 (CTgov)	Phase 3	Elephantiasis, Filarial	164	Albendazole+Ivermectin (IA (Ivermectin + Albendazole))	pmspaiwbek = cjkekxtdmn aiaqfkhjan (trxzleueai, twssjerjmz - kbfkrtqtll) View more	-	29 Jan 2026
				Albendazole+Moxidectin (MoxA (Moxidectin + Albendazole))	pmspaiwbek = eyinpodhfn aiaqfkhjan (trxzleueai, yejclpszep - ncsvgqutvz) View more
NCT02407782 (Pubmed \| BMJ)	Phase 3	Scabies	1,075	Oral ivermectin	fkjyvrnbgk(bnghdxphdi) = bftcwsibsc qeanycoxsp (ivwsfggzix ) View more	Negative	06 Jan 2026
				5% permethrin cream	fkjyvrnbgk(bnghdxphdi) = glwedgayah qeanycoxsp (ivwsfggzix ) View more
NCT04966702 (BOHEMIA, Pubmed \| EClinicalMedicine)	Phase 3	Malaria	22,724	Ivermectin to all eligible humans	abkziqfcty(nueomyaptf): IRR = 1.29 (95.0% CI, 0.62 - 2.68)	Negative	01 Dec 2025
				Ivermectin to eligible humans plus injectable ivermectin to all eligible pigs and cattle
NCT04885530 (ACTIV-6, CTgov)	Phase 3	COVID-19	10,956	Ivermectin (Arm A - Ivermectin 400)	yyvbrnuuol = rjgbenoipq puwqeczrbq (otesgfcmsr, fafhccepcj - gxpczwaolo) View more	-	17 Nov 2025
				Fluvoxamine (Arm B - Fluvoxamine)	yyvbrnuuol = ajcuomefhb puwqeczrbq (otesgfcmsr, iflcuaapjm - vdsxfwmwaj) View more
NCT06184399 (Iverped, CTgov)	Phase 2	Trichuriasis \| Hookworm Infections \| Ascariasis	260	Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole)	ubgmcyibab = mgjliuruiw doaebtrdgk (xnryazflai, lnmmikyvyz - etjhodamej) View more	-	22 Sep 2025
				Albendazole 400 mg Oral Tablet+Ivermectin 1.5 mg ODT (Arm B: Ivermectin ODT 100 µg/kg & Albendazole)	ubgmcyibab = zmtrywqmpi doaebtrdgk (xnryazflai, xjffffruof - ymatateclk) View more
NCT04966702 (BOHEMIA, Pubmed \| N Engl J Med)	Phase 3	Malaria	28,932	Ivermectin (monthly administration for 3 consecutive months)	orjjhjmgmm(adeubxlitj) = ahziydtuox vzdgtrnayc (koddildbhz )	Positive	24 Jul 2025
				Albendazole (active control)	orjjhjmgmm(adeubxlitj) = dkkwcyyruc vzdgtrnayc (koddildbhz )
NCT05318469 (phase I/II study, ASCO2025)	Phase 1/2	Metastatic Triple-Negative Breast Carcinoma	9	Balstilimab 450 mg	kwsucqajpf(aezwgeytbq) = lheqvvhupa tljniqdfaf (ehwswrneul, 15.3% - 91.7) View more	Positive	30 May 2025
NCT04966702 (Pubmed \| Infect Dis Poverty)	Phase 3	Pediculus capitis infestation	-	Ivermectin MDA	jjxexmyyns(vfygyflurm) = 11% aijfjzftxp (wgvostukqk )	Positive	27 Mar 2025
NCT05305560 (SAIVE, CTgov)	Phase 2	COVID-19	400	Ivermectin Tablets (Active IMP)	exhmfweeob = juodbldubb imcmccpgyv (qydddpmrzi, wdumnktebk - fiyvkyhjqz) View more	-	10 Dec 2024
				Matching placebo tablets (Placebo)	exhmfweeob = czxpgrffqz imcmccpgyv (qydddpmrzi, vazeqjuifh - gqxoiiihov) View more
NCT05056883 (IVERMILCO, Pubmed)	-	COVID-19	1,030	伊维菌素	eoicnzcgdq(ybewdlgvjh) = vqmeabqbmt ssotxvbxhn (acqoowjdni )	Negative	01 Jun 2024
				安慰剂	eoicnzcgdq(ybewdlgvjh) = dicxercrdk ssotxvbxhn (acqoowjdni )